Short answer
Protara Therapeutics, Inc. (TARA) filed an 8-K current report with the SEC on November 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Protara announced financial results for the quarter ended September 30, 2026.
Protara Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Protara announced financial results for the quarter ended September 30, 2026
- Full results and management commentary are in Exhibit 99.1, the accompanying earnings release
Item EX-99.1 · Exhibit EX-99.1
- TARA-002 NMIBC enrollment targeted for Q4 2026, a key catalyst for registrational ADVANCED-2 progress
- STARBORN-1 LM enrollment pushed to early Q1 2027, with rolling BLA submission still planned for 2H 2027
- THRIVE-3 Phase 2b cohort enrolled 24 patients, with interim results expected in Q4 2026
- $8.75 million acquisition of TARA-002 manufacturing assets brings production in-house and secures capacity ahead of potential launch
- Cash, equivalents and investments $143.1 million, funding planned operations into 2028 despite Q3 net loss of $21.7 million
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Protara Therapeutics, Inc. 8-K filings
Get the next TARA 8-K as it lands
Follow TARA for push alerts, or ask the research agent what this filing means.